|
| S. Number | Carrier system | Advantages/results obtained |
|
| 1. | Liposome-mediated delivery [87] | Sustained anti-inflammatory activity |
| 2. | Ethosomes-mediated delivery [69–72] | Enhancement in Skin Permeation, Improvement in Anti-Inflammatory Efficacy |
| 3. | Microemulsion and nanoemulsion-mediated delivery [74–77] | Biocompatible, enhanced skin permeability, andefficacy |
| 4. | Niosome-based delivery [81, 82, 87] | Enhanced permeability, efficacy, and stability vis-à-vis liposomes |
| 5. | Organogel-based delivery [83, 84, 86] | Superior efficacy andstability, nonirritant |
| 6. | Liposphere-based delivery [87] | Enhanced stability, permeability, drug entrapment, andefficacy |
| 7. | Nanostructured lipid carriers- (NLC-) based delivery [86] | Fast onset of action, sustained duration of action, nonirritant vis-à-vis the marketed products |
| 8. | Solid lipid nanoparticles-mediated delivery [89] | Sustained drug release, better rheology |
|
